Anpocogin clinical trials
Also written AB-201 and rNAPc2.
How each study uses anpocogin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the anpocogin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2005 (1)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2006 | 1 |
| 2020 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 1
ARCA Biopharma, Inc. (3) · Yonsei University (1) · Artiva Biotherapeutics, Inc. (1) · GC Cell Corporation (1)
Studies
Open first, then newest update. How each study uses anpocogin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Clinical Study to Evaluate the Safety and Anti-Tumor Activity of AB-201Not yet recruitingPhase 1Yonsei UniversityNCT07333820Written as AB-201 Dose escalationHow we know
- A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid TumorsWithdrawnPhase 1/2Artiva Biotherapeutics, Inc.NCT05678205Written as AB-201How we know
- Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201WithdrawnPhase 1GC Cell CorporationNCT06341647Written as AB-201How we know
- Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19CompletedPhase 2/3ARCA Biopharma, Inc.NCT04655586Written as rNAPc2How we know
- Safety Study of Recombinant NAPc2 to Prevent Tumor Progression and Metastases in Metastatic Colon CancerSuspendedPhase 1/2ARCA Biopharma, Inc.NCT00443573Written as recombinant nematode anticoagulant protein c2 (rNAPc2)How we know
- Anticoagulation With rNAPc2 to Eliminate MACE/TIMI 32CompletedPhase 2ARCA Biopharma, Inc.NCT00116012Written as rNAPc2How we know
Codes
What other systems call anpocogin · ClinicalTrials.gg INT014729
- UNII (FDA) 3TTT9ZD93FANPOCOGINOne source FDA
- NCI Thesaurus C69129AnpocoginOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 3TTT9ZD93F | ANPOCOGIN | One source FDA |
| NCI Thesaurus | C69129 | Anpocogin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.